

## Anesthetic and Analgesic Drug Products Advisory Committee Activity and Decisions in the Opioid-crisis Era: Erratum

In the article beginning on page 740 in the October 2020 issue, there is an error in the “Oliceridine” section and in Table 2. In the third paragraph of the “Oliceridine” section on page 745, “... (at the time of this writing, the Food and Drug Administration has not publicly responded to the resubmission)” should be replaced by “Oliceridine has now been approved by the Food and Drug administration in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.” Additionally, in the first “October 2018” row in Table 2 on page 742, “Not approved” should be replaced by “Approved after resubmission.”

The online version and PDF of the article have been corrected.

DOI: 10.1097/ALN.0000000000003599

### Reference

Litman RS: Anesthetic and Analgesic Drug Products Advisory Committee activity and decisions in the opioid-crisis era. *ANESTHESIOLOGY* 2020; 133:740–9